- Home
- ULS vs EXAS Comparison
ULS vs EXAS Comparison
Compare ULS & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULS
- EXAS
- Stock Information
- Founded
- ULS 1894
- EXAS 1995
- Country
- ULS United States
- EXAS United States
- Employees
- ULS N/A
- EXAS N/A
- Industry
- ULS
- EXAS Medical Specialities
- Sector
- ULS
- EXAS Health Care
- Exchange
- ULS Nasdaq
- EXAS Nasdaq
- Market Cap
- ULS 14.6B
- EXAS 10.2B
- IPO Year
- ULS 2024
- EXAS N/A
- Fundamental
- Price
- ULS $68.05
- EXAS $53.16
- Analyst Decision
- ULS Buy
- EXAS Strong Buy
- Analyst Count
- ULS 8
- EXAS 22
- Target Price
- ULS $69.25
- EXAS $67.38
- AVG Volume (30 Days)
- ULS 733.0K
- EXAS 2.8M
- Earning Date
- ULS 11-04-2025
- EXAS 11-04-2025
- Dividend Yield
- ULS 0.77%
- EXAS N/A
- EPS Growth
- ULS 21.42
- EXAS N/A
- EPS
- ULS 1.62
- EXAS N/A
- Revenue
- ULS $2,951,000,000.00
- EXAS $2,939,949,000.00
- Revenue This Year
- ULS $6.69
- EXAS $16.68
- Revenue Next Year
- ULS $6.24
- EXAS $12.08
- P/E Ratio
- ULS $41.52
- EXAS N/A
- Revenue Growth
- ULS 6.92
- EXAS 12.55
- 52 Week Low
- ULS $48.11
- EXAS $38.81
- 52 Week High
- ULS $74.15
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- ULS 56.67
- EXAS 59.29
- Support Level
- ULS $66.17
- EXAS $52.11
- Resistance Level
- ULS $68.43
- EXAS $56.52
- Average True Range (ATR)
- ULS 1.79
- EXAS 1.66
- MACD
- ULS 0.60
- EXAS 0.15
- Stochastic Oscillator
- ULS 93.81
- EXAS 66.73
About ULS UL Solutions Inc.
UL Solutions is a global leader specializing in a broad range of product testing, inspection, and certification services. UL Solutions is the for-profit branch out of three organizations under the UL Enterprise. TIC operations make up nearly all of UL Solutions' total revenue and are composed of two segments: industrial and consumer. UL Solutions' remaining business includes software and advisory, which complements its core TIC offerings. The firm operates globally.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.